Floatz logo

Recombinant Human Adenovirus Type 5

Hepatocellular Carcinoma

Henan Cancer Hospitalgene_therapyPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
Carboplatin
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human Adenovirus Type 5 is also rated in:

melanomaDormant
B
Indicative ·
58 / 100
View asset →
portal vein thrombosisDormant
CCC
Indicative ·
53 / 100
View asset →
Liver MetastasesDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →